Sean Donahue
Concepts (542)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vision Screening | 37 | 2025 | 46 | 10.370 |
Why?
| | Amblyopia | 42 | 2025 | 54 | 9.400 |
Why?
| | Oculomotor Muscles | 29 | 2024 | 75 | 9.110 |
Why?
| | Ophthalmologic Surgical Procedures | 23 | 2024 | 84 | 6.530 |
Why?
| | Strabismus | 28 | 2026 | 65 | 6.060 |
Why?
| | Exotropia | 15 | 2023 | 20 | 5.310 |
Why?
| | Esotropia | 13 | 2023 | 25 | 4.590 |
Why?
| | Refractive Errors | 14 | 2022 | 35 | 3.300 |
Why?
| | Ophthalmology | 12 | 2026 | 106 | 3.130 |
Why?
| | Visual Acuity | 44 | 2025 | 449 | 3.110 |
Why?
| | Head | 5 | 2022 | 118 | 2.460 |
Why?
| | Posture | 6 | 2022 | 193 | 2.460 |
Why?
| | Hyperopia | 12 | 2022 | 17 | 2.270 |
Why?
| | Anisometropia | 14 | 2022 | 16 | 2.090 |
Why?
| | Retinopathy of Prematurity | 7 | 2023 | 161 | 2.090 |
Why?
| | Visual Field Tests | 13 | 2024 | 34 | 2.080 |
Why?
| | Vision Disorders | 12 | 2019 | 168 | 2.040 |
Why?
| | Nystagmus, Pathologic | 3 | 2022 | 17 | 2.000 |
Why?
| | Vision, Binocular | 17 | 2024 | 41 | 1.860 |
Why?
| | Child, Preschool | 75 | 2023 | 11511 | 1.820 |
Why?
| | Visual Fields | 17 | 2024 | 117 | 1.600 |
Why?
| | Infant | 56 | 2023 | 9820 | 1.580 |
Why?
| | Eye Abnormalities | 3 | 2019 | 17 | 1.560 |
Why?
| | Ocular Motility Disorders | 6 | 2022 | 33 | 1.480 |
Why?
| | Endophthalmitis | 12 | 2021 | 45 | 1.390 |
Why?
| | Child | 71 | 2026 | 22390 | 1.350 |
Why?
| | Eye Movements | 11 | 2021 | 87 | 1.350 |
Why?
| | Eyeglasses | 12 | 2014 | 22 | 1.330 |
Why?
| | Advisory Committees | 4 | 2018 | 214 | 1.310 |
Why?
| | Diplopia | 6 | 2024 | 26 | 1.290 |
Why?
| | Nystagmus, Congenital | 2 | 2020 | 2 | 1.270 |
Why?
| | Eye Infections, Fungal | 7 | 2021 | 20 | 1.270 |
Why?
| | Head Movements | 4 | 2020 | 32 | 1.260 |
Why?
| | Humans | 181 | 2026 | 141284 | 1.210 |
Why?
| | Myopia | 5 | 2021 | 55 | 1.160 |
Why?
| | Follow-Up Studies | 28 | 2023 | 5222 | 1.110 |
Why?
| | Astigmatism | 6 | 2021 | 17 | 1.070 |
Why?
| | Virtual Reality | 3 | 2024 | 75 | 1.040 |
Why?
| | Referral and Consultation | 10 | 2020 | 802 | 1.020 |
Why?
| | Predictive Value of Tests | 19 | 2022 | 2069 | 0.980 |
Why?
| | Tenotomy | 3 | 2019 | 19 | 0.970 |
Why?
| | Retrospective Studies | 35 | 2024 | 16447 | 0.900 |
Why?
| | Photography | 6 | 2008 | 114 | 0.890 |
Why?
| | Preventive Health Services | 3 | 2018 | 154 | 0.880 |
Why?
| | Pediatrics | 3 | 2026 | 1102 | 0.870 |
Why?
| | Papilledema | 3 | 2021 | 42 | 0.860 |
Why?
| | Trochlear Nerve Diseases | 2 | 2023 | 9 | 0.860 |
Why?
| | False Positive Reactions | 12 | 2021 | 122 | 0.860 |
Why?
| | Treatment Outcome | 33 | 2025 | 11216 | 0.860 |
Why?
| | Societies, Medical | 4 | 2026 | 859 | 0.850 |
Why?
| | Fungemia | 5 | 2011 | 9 | 0.840 |
Why?
| | Sensitivity and Specificity | 13 | 2023 | 1973 | 0.820 |
Why?
| | Tendons | 3 | 2014 | 123 | 0.820 |
Why?
| | Abnormalities, Multiple | 3 | 2016 | 197 | 0.810 |
Why?
| | Basal Cell Nevus Syndrome | 2 | 2014 | 7 | 0.780 |
Why?
| | Diagnostic Techniques, Ophthalmological | 4 | 2015 | 50 | 0.770 |
Why?
| | Male | 75 | 2024 | 70140 | 0.730 |
Why?
| | Optic Disk | 2 | 2021 | 52 | 0.730 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 113 | 0.730 |
Why?
| | Candidiasis | 5 | 2019 | 62 | 0.720 |
Why?
| | Lens Implantation, Intraocular | 3 | 2008 | 67 | 0.690 |
Why?
| | Atropine | 6 | 2011 | 36 | 0.690 |
Why?
| | Risk Factors | 20 | 2023 | 10490 | 0.680 |
Why?
| | Education, Medical, Graduate | 1 | 2026 | 529 | 0.680 |
Why?
| | Glaucoma Drainage Implants | 1 | 2020 | 45 | 0.630 |
Why?
| | Female | 66 | 2024 | 75814 | 0.630 |
Why?
| | Trabeculectomy | 1 | 2020 | 74 | 0.610 |
Why?
| | Eye Diseases | 2 | 2020 | 93 | 0.590 |
Why?
| | Eyelids | 1 | 2019 | 42 | 0.590 |
Why?
| | Remote Consultation | 1 | 2020 | 63 | 0.590 |
Why?
| | Adolescent | 29 | 2024 | 22116 | 0.580 |
Why?
| | Prevalence | 13 | 2025 | 2795 | 0.570 |
Why?
| | Hemianopsia | 2 | 2008 | 11 | 0.560 |
Why?
| | Fixation, Ocular | 5 | 2020 | 26 | 0.560 |
Why?
| | Duane Retraction Syndrome | 1 | 2017 | 1 | 0.550 |
Why?
| | Chorioretinitis | 4 | 2011 | 8 | 0.550 |
Why?
| | Bandages | 3 | 2016 | 42 | 0.540 |
Why?
| | Charities | 2 | 2008 | 12 | 0.530 |
Why?
| | Diabetic Retinopathy | 1 | 2020 | 202 | 0.530 |
Why?
| | Tonic Pupil | 1 | 2016 | 1 | 0.520 |
Why?
| | Retina | 4 | 2016 | 314 | 0.520 |
Why?
| | Glaucoma | 5 | 2021 | 242 | 0.510 |
Why?
| | Sleep Apnea, Central | 1 | 2016 | 13 | 0.510 |
Why?
| | Hypoventilation | 1 | 2016 | 12 | 0.510 |
Why?
| | Practice Guidelines as Topic | 6 | 2021 | 1546 | 0.510 |
Why?
| | Mydriatics | 6 | 2011 | 9 | 0.510 |
Why?
| | Kidney Diseases, Cystic | 1 | 2016 | 25 | 0.510 |
Why?
| | Ophthalmic Solutions | 3 | 2015 | 80 | 0.500 |
Why?
| | Technology Assessment, Biomedical | 2 | 2016 | 39 | 0.500 |
Why?
| | Retinal Neoplasms | 2 | 2013 | 36 | 0.480 |
Why?
| | Retinoblastoma | 2 | 2013 | 40 | 0.480 |
Why?
| | Infant, Newborn | 13 | 2023 | 6270 | 0.480 |
Why?
| | Depth Perception | 4 | 2017 | 4 | 0.480 |
Why?
| | Ophthalmoplegia | 4 | 2001 | 13 | 0.470 |
Why?
| | Refraction, Ocular | 3 | 2011 | 43 | 0.470 |
Why?
| | Hirschsprung Disease | 1 | 2016 | 85 | 0.470 |
Why?
| | Prescriptions | 2 | 2007 | 74 | 0.460 |
Why?
| | Eye Neoplasms | 1 | 2015 | 28 | 0.460 |
Why?
| | Sensory Deprivation | 7 | 2011 | 15 | 0.450 |
Why?
| | Lens, Crystalline | 2 | 2008 | 133 | 0.450 |
Why?
| | Uveitis, Anterior | 1 | 2015 | 24 | 0.450 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 25 | 0.450 |
Why?
| | Mass Screening | 3 | 2020 | 1309 | 0.450 |
Why?
| | Conjunctiva | 1 | 2015 | 53 | 0.450 |
Why?
| | Cerebellum | 1 | 2016 | 217 | 0.440 |
Why?
| | Optic Nerve Diseases | 5 | 2021 | 47 | 0.440 |
Why?
| | Pseudophakia | 1 | 2014 | 16 | 0.440 |
Why?
| | Tensile Strength | 1 | 2014 | 96 | 0.420 |
Why?
| | Reproducibility of Results | 10 | 2024 | 3345 | 0.420 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 80 | 0.420 |
Why?
| | Evoked Potentials, Visual | 1 | 2013 | 40 | 0.400 |
Why?
| | Adult | 34 | 2024 | 39319 | 0.400 |
Why?
| | Gestational Age | 5 | 2023 | 952 | 0.400 |
Why?
| | Optic Atrophy, Hereditary, Leber | 2 | 2023 | 7 | 0.400 |
Why?
| | Telemedicine | 2 | 2020 | 893 | 0.390 |
Why?
| | Eye Infections, Bacterial | 5 | 1998 | 45 | 0.390 |
Why?
| | Down Syndrome | 1 | 2019 | 504 | 0.380 |
Why?
| | Botulinum Toxins | 1 | 2013 | 45 | 0.370 |
Why?
| | Stress, Mechanical | 1 | 2014 | 487 | 0.370 |
Why?
| | Angiogenesis Inhibitors | 2 | 2010 | 229 | 0.360 |
Why?
| | Age Factors | 8 | 2021 | 3295 | 0.360 |
Why?
| | Chin | 2 | 2022 | 7 | 0.350 |
Why?
| | Magnetic Resonance Imaging | 10 | 2019 | 3734 | 0.340 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2011 | 91 | 0.340 |
Why?
| | Cataract | 2 | 2023 | 223 | 0.330 |
Why?
| | Leukemic Infiltration | 2 | 2015 | 10 | 0.330 |
Why?
| | Candidemia | 2 | 2021 | 14 | 0.330 |
Why?
| | Reoperation | 4 | 2020 | 599 | 0.330 |
Why?
| | Vestibular Nuclei | 1 | 2010 | 7 | 0.320 |
Why?
| | Oculomotor Nerve Diseases | 2 | 2021 | 13 | 0.320 |
Why?
| | Optic Neuritis | 4 | 1999 | 46 | 0.320 |
Why?
| | Intraocular Pressure | 3 | 2021 | 315 | 0.310 |
Why?
| | Central Venous Pressure | 1 | 2009 | 15 | 0.310 |
Why?
| | Wet Macular Degeneration | 1 | 2010 | 57 | 0.310 |
Why?
| | Zellweger Syndrome | 1 | 2009 | 2 | 0.310 |
Why?
| | Jugular Veins | 1 | 2009 | 42 | 0.310 |
Why?
| | Artifacts | 2 | 2021 | 133 | 0.300 |
Why?
| | Vitamin A Deficiency | 1 | 2009 | 26 | 0.300 |
Why?
| | Anterior Chamber | 2 | 2008 | 26 | 0.300 |
Why?
| | Corneal Ulcer | 1 | 2009 | 21 | 0.300 |
Why?
| | Incidence | 8 | 2021 | 2809 | 0.300 |
Why?
| | Infant, Premature | 2 | 2023 | 599 | 0.290 |
Why?
| | Observation | 3 | 2016 | 56 | 0.290 |
Why?
| | Accommodation, Ocular | 2 | 2020 | 14 | 0.290 |
Why?
| | Prospective Studies | 18 | 2024 | 7805 | 0.290 |
Why?
| | Postoperative Complications | 6 | 2010 | 2831 | 0.290 |
Why?
| | Tennessee | 6 | 2008 | 52 | 0.290 |
Why?
| | Phakic Intraocular Lenses | 1 | 2008 | 1 | 0.280 |
Why?
| | Neural Pathways | 1 | 2010 | 302 | 0.280 |
Why?
| | Optometry | 2 | 2006 | 9 | 0.280 |
Why?
| | Hyperglycinemia, Nonketotic | 1 | 2008 | 55 | 0.280 |
Why?
| | United States | 11 | 2026 | 15298 | 0.270 |
Why?
| | Internationality | 1 | 2008 | 156 | 0.270 |
Why?
| | Cellulitis | 2 | 1998 | 55 | 0.270 |
Why?
| | Blindness, Cortical | 1 | 2007 | 6 | 0.270 |
Why?
| | Acrocephalosyndactylia | 1 | 2007 | 12 | 0.260 |
Why?
| | Tomography, Optical Coherence | 3 | 2021 | 258 | 0.260 |
Why?
| | Fovea Centralis | 4 | 2010 | 23 | 0.260 |
Why?
| | Pupil | 4 | 2000 | 22 | 0.250 |
Why?
| | Antibodies, Monoclonal | 2 | 2010 | 1456 | 0.240 |
Why?
| | Face | 1 | 2007 | 174 | 0.240 |
Why?
| | Oculomotor Nerve | 2 | 2021 | 7 | 0.240 |
Why?
| | Foundations | 1 | 2006 | 28 | 0.240 |
Why?
| | Eye Protective Devices | 2 | 2016 | 8 | 0.240 |
Why?
| | Diabetes Insipidus | 1 | 2005 | 6 | 0.240 |
Why?
| | Photorefractive Keratectomy | 1 | 2006 | 20 | 0.240 |
Why?
| | Septo-Optic Dysplasia | 1 | 2005 | 5 | 0.240 |
Why?
| | Middle Aged | 17 | 2024 | 34658 | 0.240 |
Why?
| | Visual Pathways | 3 | 2001 | 59 | 0.230 |
Why?
| | Opportunistic Infections | 1 | 2005 | 46 | 0.230 |
Why?
| | Vitreous Body | 5 | 2010 | 122 | 0.230 |
Why?
| | Marfan Syndrome | 1 | 2005 | 43 | 0.230 |
Why?
| | History, 21st Century | 1 | 2026 | 218 | 0.220 |
Why?
| | Practice Patterns, Physicians' | 2 | 2004 | 1336 | 0.220 |
Why?
| | Reflex, Vestibulo-Ocular | 2 | 2001 | 26 | 0.220 |
Why?
| | Age Distribution | 4 | 2011 | 396 | 0.220 |
Why?
| | Diagnosis, Differential | 7 | 2019 | 1491 | 0.220 |
Why?
| | Brain Concussion | 2 | 2022 | 592 | 0.220 |
Why?
| | History, 20th Century | 1 | 2026 | 324 | 0.220 |
Why?
| | Cornea | 1 | 2006 | 156 | 0.220 |
Why?
| | Canada | 1 | 2026 | 420 | 0.220 |
Why?
| | Exophthalmos | 1 | 2004 | 17 | 0.210 |
Why?
| | Leukemia, Myeloid | 1 | 2004 | 47 | 0.210 |
Why?
| | Muscles | 3 | 1991 | 331 | 0.210 |
Why?
| | Aphakia, Postcataract | 1 | 2003 | 4 | 0.210 |
Why?
| | Contact Lenses | 1 | 2003 | 11 | 0.210 |
Why?
| | Nerve Fibers | 2 | 2021 | 100 | 0.210 |
Why?
| | Graves Ophthalmopathy | 1 | 2024 | 13 | 0.210 |
Why?
| | Medical Records | 2 | 2007 | 185 | 0.210 |
Why?
| | Retinoscopy | 2 | 2016 | 3 | 0.210 |
Why?
| | Infant, Very Low Birth Weight | 2 | 2023 | 70 | 0.210 |
Why?
| | Tonometry, Ocular | 2 | 2021 | 103 | 0.210 |
Why?
| | Tomography, X-Ray Computed | 8 | 2014 | 2765 | 0.200 |
Why?
| | Xanthomatosis, Cerebrotendinous | 1 | 2023 | 5 | 0.200 |
Why?
| | Iris | 2 | 2005 | 22 | 0.200 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2024 | 908 | 0.200 |
Why?
| | Pseudotumor Cerebri | 2 | 2000 | 31 | 0.200 |
Why?
| | Combined Modality Therapy | 4 | 2013 | 1243 | 0.200 |
Why?
| | Birth Weight | 2 | 2023 | 511 | 0.200 |
Why?
| | Hematoma, Subdural | 2 | 2000 | 20 | 0.200 |
Why?
| | Retinal Hemorrhage | 2 | 2000 | 22 | 0.200 |
Why?
| | Parvovirinae | 1 | 2022 | 5 | 0.200 |
Why?
| | Paralysis | 1 | 2023 | 70 | 0.190 |
Why?
| | Young Adult | 6 | 2023 | 13727 | 0.190 |
Why?
| | Aging | 3 | 2011 | 1919 | 0.190 |
Why?
| | Ophthalmologists | 1 | 2022 | 13 | 0.180 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 2 | 2019 | 266 | 0.180 |
Why?
| | Eye Diseases, Hereditary | 1 | 2021 | 13 | 0.180 |
Why?
| | Receptors, Angiotensin | 1 | 2001 | 11 | 0.180 |
Why?
| | Neonatal Screening | 1 | 2023 | 172 | 0.180 |
Why?
| | Physicians' Offices | 2 | 2016 | 18 | 0.180 |
Why?
| | Pandemics | 2 | 2020 | 1655 | 0.180 |
Why?
| | Vitrectomy | 3 | 2005 | 78 | 0.180 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2001 | 55 | 0.180 |
Why?
| | Intubation | 2 | 2014 | 6 | 0.180 |
Why?
| | Optic Neuropathy, Ischemic | 1 | 2001 | 31 | 0.170 |
Why?
| | Dacryocystorhinostomy | 2 | 2014 | 12 | 0.170 |
Why?
| | Nasolacrimal Duct | 2 | 2014 | 10 | 0.170 |
Why?
| | Academies and Institutes | 1 | 2021 | 54 | 0.170 |
Why?
| | Pilot Projects | 5 | 2021 | 1820 | 0.170 |
Why?
| | Daucus carota | 1 | 2000 | 2 | 0.170 |
Why?
| | Aphakia | 1 | 2000 | 2 | 0.170 |
Why?
| | Sports Medicine | 1 | 2022 | 117 | 0.170 |
Why?
| | Retinal Ganglion Cells | 1 | 2021 | 117 | 0.170 |
Why?
| | Postoperative Period | 2 | 2020 | 359 | 0.170 |
Why?
| | Battered Child Syndrome | 1 | 2000 | 7 | 0.160 |
Why?
| | Masks | 1 | 2021 | 69 | 0.160 |
Why?
| | United Arab Emirates | 1 | 2020 | 7 | 0.160 |
Why?
| | Subarachnoid Hemorrhage, Traumatic | 1 | 1999 | 4 | 0.160 |
Why?
| | Videoconferencing | 1 | 2020 | 66 | 0.160 |
Why?
| | Low Tension Glaucoma | 1 | 2019 | 1 | 0.160 |
Why?
| | Horner Syndrome | 2 | 1996 | 6 | 0.160 |
Why?
| | Vision, Ocular | 1 | 2000 | 45 | 0.160 |
Why?
| | Leukomalacia, Periventricular | 1 | 2019 | 9 | 0.160 |
Why?
| | Sex Distribution | 2 | 2011 | 381 | 0.160 |
Why?
| | Planning Techniques | 1 | 2019 | 16 | 0.160 |
Why?
| | Sports | 1 | 2022 | 219 | 0.160 |
Why?
| | Glaucoma, Open-Angle | 1 | 2021 | 104 | 0.150 |
Why?
| | Bacteremia | 2 | 2019 | 218 | 0.150 |
Why?
| | Physical Examination | 2 | 2019 | 243 | 0.150 |
Why?
| | Syndrome | 1 | 2020 | 376 | 0.150 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 237 | 0.150 |
Why?
| | Temporal Lobe | 1 | 1999 | 104 | 0.150 |
Why?
| | Eye Infections, Viral | 1 | 1998 | 11 | 0.150 |
Why?
| | Electroretinography | 1 | 1998 | 51 | 0.150 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 1998 | 18 | 0.150 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 1998 | 21 | 0.140 |
Why?
| | Polymorphism, Genetic | 1 | 2001 | 619 | 0.140 |
Why?
| | Costs and Cost Analysis | 1 | 2019 | 219 | 0.140 |
Why?
| | Orbital Diseases | 1 | 1998 | 32 | 0.140 |
Why?
| | Eyelid Diseases | 1 | 1998 | 23 | 0.140 |
Why?
| | Aged | 8 | 2024 | 24836 | 0.140 |
Why?
| | Haemophilus Infections | 1 | 1998 | 41 | 0.140 |
Why?
| | Motion Perception | 1 | 1998 | 18 | 0.140 |
Why?
| | Pupil Disorders | 1 | 1997 | 7 | 0.140 |
Why?
| | Neuromuscular Junction | 2 | 1988 | 65 | 0.140 |
Why?
| | Staphylococcal Infections | 2 | 2022 | 390 | 0.140 |
Why?
| | Intracranial Hypertension | 1 | 1998 | 41 | 0.140 |
Why?
| | Retinal Diseases | 1 | 1998 | 96 | 0.140 |
Why?
| | Fatal Outcome | 2 | 2015 | 309 | 0.140 |
Why?
| | Craniocerebral Trauma | 1 | 1999 | 175 | 0.130 |
Why?
| | Spleen | 1 | 2019 | 512 | 0.130 |
Why?
| | Hydrocephalus | 2 | 2010 | 110 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2010 | 547 | 0.130 |
Why?
| | Chronic Disease | 1 | 2023 | 1807 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 910 | 0.130 |
Why?
| | p-Hydroxyamphetamine | 1 | 1996 | 1 | 0.130 |
Why?
| | Quality of Life | 5 | 2022 | 3024 | 0.130 |
Why?
| | Synapses | 3 | 1991 | 428 | 0.130 |
Why?
| | Conjunctivitis, Viral | 1 | 1996 | 3 | 0.130 |
Why?
| | International Classification of Diseases | 1 | 2018 | 141 | 0.130 |
Why?
| | Conjunctivitis, Bacterial | 1 | 1996 | 13 | 0.130 |
Why?
| | Keratitis | 1 | 1996 | 22 | 0.120 |
Why?
| | Sarcopenia | 1 | 2018 | 82 | 0.120 |
Why?
| | Wounds, Nonpenetrating | 1 | 1999 | 309 | 0.120 |
Why?
| | Volunteers | 2 | 2010 | 39 | 0.120 |
Why?
| | Severity of Illness Index | 5 | 2019 | 2904 | 0.120 |
Why?
| | Eye Foreign Bodies | 2 | 1994 | 26 | 0.120 |
Why?
| | Retinal Detachment | 2 | 1997 | 74 | 0.120 |
Why?
| | Sensory Thresholds | 4 | 1999 | 32 | 0.120 |
Why?
| | Respiration, Artificial | 1 | 2021 | 689 | 0.120 |
Why?
| | Proteomics | 1 | 2023 | 1137 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 1035 | 0.120 |
Why?
| | Piperazines | 1 | 1998 | 375 | 0.120 |
Why?
| | Athletic Injuries | 1 | 2022 | 527 | 0.120 |
Why?
| | Vitamin A | 2 | 2009 | 56 | 0.120 |
Why?
| | Prognosis | 4 | 2015 | 4080 | 0.120 |
Why?
| | Aged, 80 and over | 3 | 2020 | 7948 | 0.120 |
Why?
| | Prosthesis Implantation | 1 | 1997 | 156 | 0.120 |
Why?
| | Biopsy, Needle | 2 | 2011 | 189 | 0.120 |
Why?
| | Myelinolysis, Central Pontine | 1 | 1995 | 3 | 0.110 |
Why?
| | Functional Laterality | 2 | 2011 | 242 | 0.110 |
Why?
| | Weight Loss | 1 | 2000 | 794 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 1998 | 835 | 0.110 |
Why?
| | Epilepsy | 1 | 1999 | 359 | 0.110 |
Why?
| | Recurrence | 3 | 2011 | 1108 | 0.110 |
Why?
| | Orthoptics | 1 | 2014 | 1 | 0.110 |
Why?
| | Anti-Bacterial Agents | 2 | 1996 | 1866 | 0.110 |
Why?
| | Parents | 1 | 2003 | 1439 | 0.110 |
Why?
| | Antifungal Agents | 2 | 2011 | 144 | 0.110 |
Why?
| | Retinal Neovascularization | 1 | 1994 | 28 | 0.100 |
Why?
| | Polycystic Kidney Diseases | 1 | 2014 | 73 | 0.100 |
Why?
| | Cephalosporins | 1 | 1994 | 45 | 0.100 |
Why?
| | Cryotherapy | 1 | 2013 | 18 | 0.100 |
Why?
| | Infusions, Intra-Arterial | 1 | 2013 | 61 | 0.100 |
Why?
| | Developmental Disabilities | 1 | 2016 | 288 | 0.100 |
Why?
| | Algorithms | 1 | 2001 | 1764 | 0.100 |
Why?
| | Vancomycin | 1 | 1994 | 92 | 0.100 |
Why?
| | Anti-Dyskinesia Agents | 1 | 2013 | 8 | 0.100 |
Why?
| | Facial Paralysis | 1 | 1993 | 24 | 0.100 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 1993 | 60 | 0.100 |
Why?
| | Bevacizumab | 2 | 2010 | 135 | 0.100 |
Why?
| | Interferon-alpha | 1 | 1994 | 195 | 0.100 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 1993 | 75 | 0.100 |
Why?
| | Acute Disease | 4 | 2004 | 1005 | 0.100 |
Why?
| | Conjunctival Diseases | 1 | 1992 | 21 | 0.100 |
Why?
| | Silicone Oils | 1 | 1992 | 32 | 0.090 |
Why?
| | Translocation, Genetic | 1 | 1993 | 109 | 0.090 |
Why?
| | Injections, Intramuscular | 1 | 2013 | 140 | 0.090 |
Why?
| | Dependovirus | 2 | 2023 | 76 | 0.090 |
Why?
| | Brain Ischemia | 1 | 1996 | 351 | 0.090 |
Why?
| | Brain | 2 | 2001 | 2857 | 0.090 |
Why?
| | Hyperthermia, Induced | 1 | 2013 | 120 | 0.090 |
Why?
| | Glucocorticoids | 2 | 2015 | 534 | 0.090 |
Why?
| | Macular Degeneration | 1 | 1994 | 186 | 0.090 |
Why?
| | Recovery of Function | 2 | 2010 | 684 | 0.090 |
Why?
| | Sarcoidosis | 1 | 1993 | 162 | 0.090 |
Why?
| | Administration, Oral | 2 | 2009 | 825 | 0.080 |
Why?
| | Ranibizumab | 1 | 2010 | 20 | 0.080 |
Why?
| | Genetic Therapy | 2 | 2023 | 315 | 0.080 |
Why?
| | Health Records, Personal | 1 | 2010 | 28 | 0.080 |
Why?
| | Los Angeles | 1 | 2010 | 75 | 0.080 |
Why?
| | Remission, Spontaneous | 1 | 2010 | 40 | 0.080 |
Why?
| | Seizures | 2 | 2007 | 441 | 0.080 |
Why?
| | Patient Care Management | 1 | 2010 | 55 | 0.080 |
Why?
| | TRPP Cation Channels | 1 | 2010 | 81 | 0.080 |
Why?
| | Orbit | 1 | 2010 | 70 | 0.080 |
Why?
| | Saccule and Utricle | 1 | 2010 | 13 | 0.080 |
Why?
| | Torsion Abnormality | 1 | 2010 | 20 | 0.080 |
Why?
| | Disease Progression | 3 | 2010 | 2808 | 0.080 |
Why?
| | Injections | 1 | 2010 | 191 | 0.080 |
Why?
| | Cysts | 1 | 2010 | 113 | 0.080 |
Why?
| | Semicircular Canals | 1 | 2010 | 33 | 0.080 |
Why?
| | Formamides | 1 | 1989 | 7 | 0.080 |
Why?
| | User-Computer Interface | 1 | 2010 | 163 | 0.080 |
Why?
| | Infratentorial Neoplasms | 1 | 2010 | 64 | 0.080 |
Why?
| | Hospitals, Veterans | 1 | 2010 | 255 | 0.070 |
Why?
| | Research Design | 2 | 2018 | 1105 | 0.070 |
Why?
| | Candida | 2 | 2019 | 41 | 0.070 |
Why?
| | Electrophysiology | 1 | 1989 | 218 | 0.070 |
Why?
| | Reflex, Pupillary | 2 | 1999 | 6 | 0.070 |
Why?
| | Hong Kong | 1 | 2008 | 8 | 0.070 |
Why?
| | Ultrasonography | 2 | 2010 | 765 | 0.070 |
Why?
| | Intermediate Filament Proteins | 1 | 1988 | 58 | 0.070 |
Why?
| | Mutation, Missense | 1 | 2010 | 337 | 0.070 |
Why?
| | Blood Pressure Determination | 1 | 2009 | 144 | 0.070 |
Why?
| | Observer Variation | 1 | 2009 | 356 | 0.070 |
Why?
| | Spinal Dysraphism | 1 | 2010 | 107 | 0.070 |
Why?
| | Brazil | 1 | 2008 | 168 | 0.070 |
Why?
| | Reference Standards | 1 | 2008 | 180 | 0.070 |
Why?
| | Vitamins | 1 | 2009 | 181 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2011 | 1610 | 0.070 |
Why?
| | Hypoxia, Brain | 1 | 2007 | 9 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 2210 | 0.070 |
Why?
| | Preoperative Care | 1 | 2010 | 372 | 0.070 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2007 | 17 | 0.060 |
Why?
| | Eye Injuries | 2 | 2000 | 53 | 0.060 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2007 | 42 | 0.060 |
Why?
| | Disease Management | 1 | 2010 | 634 | 0.060 |
Why?
| | Muscle Contraction | 1 | 1989 | 430 | 0.060 |
Why?
| | International Agencies | 1 | 2006 | 32 | 0.060 |
Why?
| | Treatment Failure | 1 | 2007 | 355 | 0.060 |
Why?
| | Jaundice, Neonatal | 1 | 2005 | 8 | 0.060 |
Why?
| | Lasers, Excimer | 1 | 2006 | 29 | 0.060 |
Why?
| | Alaska | 1 | 2006 | 85 | 0.060 |
Why?
| | Hypopituitarism | 1 | 2005 | 16 | 0.060 |
Why?
| | Double-Blind Method | 1 | 2010 | 1992 | 0.060 |
Why?
| | Eye Injuries, Penetrating | 1 | 2005 | 20 | 0.060 |
Why?
| | Central Nervous System | 1 | 2007 | 264 | 0.060 |
Why?
| | Rats, Inbred F344 | 3 | 1991 | 265 | 0.060 |
Why?
| | Reference Values | 3 | 2007 | 803 | 0.050 |
Why?
| | Legislation, Medical | 1 | 2004 | 11 | 0.050 |
Why?
| | Urinary Tract Infections | 1 | 2007 | 195 | 0.050 |
Why?
| | Kidney Failure, Chronic | 1 | 2010 | 599 | 0.050 |
Why?
| | Voluntary Health Agencies | 1 | 2004 | 6 | 0.050 |
Why?
| | Treatment Refusal | 1 | 2005 | 96 | 0.050 |
Why?
| | Withholding Treatment | 1 | 2004 | 76 | 0.050 |
Why?
| | Blood Glucose | 2 | 2008 | 2286 | 0.050 |
Why?
| | Time Factors | 3 | 2010 | 6951 | 0.050 |
Why?
| | Cholestanol | 1 | 2023 | 4 | 0.050 |
Why?
| | HIV Infections | 1 | 1998 | 2981 | 0.050 |
Why?
| | NADH Dehydrogenase | 1 | 2023 | 20 | 0.050 |
Why?
| | Decompression, Surgical | 1 | 2024 | 114 | 0.050 |
Why?
| | Premature Birth | 1 | 2007 | 363 | 0.050 |
Why?
| | Random Allocation | 1 | 2003 | 369 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2005 | 578 | 0.050 |
Why?
| | Animals | 6 | 2014 | 37328 | 0.050 |
Why?
| | Kidney | 1 | 2010 | 1482 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2010 | 2929 | 0.050 |
Why?
| | Scotoma | 2 | 1999 | 7 | 0.050 |
Why?
| | Guideline Adherence | 1 | 2007 | 560 | 0.050 |
Why?
| | Blindness | 1 | 2002 | 50 | 0.050 |
Why?
| | Saccades | 1 | 2022 | 45 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2162 | 0.050 |
Why?
| | Bile Acids and Salts | 1 | 2023 | 156 | 0.050 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 2001 | 8 | 0.040 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2001 | 23 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2023 | 209 | 0.040 |
Why?
| | Inflammation | 2 | 2023 | 2840 | 0.040 |
Why?
| | Patient Compliance | 1 | 2006 | 607 | 0.040 |
Why?
| | Genetic Vectors | 1 | 2022 | 336 | 0.040 |
Why?
| | Hypoglycemia | 1 | 2005 | 470 | 0.040 |
Why?
| | Rats | 4 | 1991 | 5556 | 0.040 |
Why?
| | Vitreous Hemorrhage | 1 | 2000 | 9 | 0.040 |
Why?
| | Geniculate Bodies | 1 | 2019 | 20 | 0.040 |
Why?
| | Microbiological Techniques | 3 | 1995 | 33 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2001 | 5653 | 0.040 |
Why?
| | Data Interpretation, Statistical | 1 | 2001 | 374 | 0.040 |
Why?
| | Pulmonary Ventilation | 1 | 2000 | 83 | 0.040 |
Why?
| | Siblings | 1 | 2020 | 216 | 0.040 |
Why?
| | Muscle Development | 2 | 1991 | 114 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 2 | 2007 | 367 | 0.040 |
Why?
| | Automation | 1 | 1999 | 101 | 0.040 |
Why?
| | Visual Cortex | 1 | 2019 | 76 | 0.040 |
Why?
| | Streptococcal Infections | 2 | 1998 | 152 | 0.040 |
Why?
| | Blood Sedimentation | 1 | 1998 | 43 | 0.040 |
Why?
| | Haemophilus Vaccines | 1 | 1998 | 30 | 0.040 |
Why?
| | Optic Nerve | 1 | 1998 | 66 | 0.040 |
Why?
| | Bacteria | 3 | 1995 | 872 | 0.040 |
Why?
| | Streptococcus | 1 | 1998 | 29 | 0.040 |
Why?
| | Sildenafil Citrate | 1 | 1998 | 59 | 0.040 |
Why?
| | Organ Size | 1 | 2019 | 476 | 0.040 |
Why?
| | Transplant Recipients | 1 | 2020 | 181 | 0.040 |
Why?
| | Brain Neoplasms | 1 | 2007 | 1282 | 0.040 |
Why?
| | Haemophilus influenzae | 1 | 1998 | 63 | 0.030 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 1998 | 24 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 273 | 0.030 |
Why?
| | Probability | 1 | 1999 | 307 | 0.030 |
Why?
| | Sulfones | 1 | 1998 | 127 | 0.030 |
Why?
| | Postoperative Care | 1 | 2019 | 280 | 0.030 |
Why?
| | Animals, Newborn | 2 | 1991 | 866 | 0.030 |
Why?
| | Purines | 1 | 1998 | 182 | 0.030 |
Why?
| | HIV | 1 | 1998 | 248 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2000 | 1268 | 0.030 |
Why?
| | Molluscum Contagiosum | 1 | 1996 | 4 | 0.030 |
Why?
| | False Negative Reactions | 1 | 1996 | 60 | 0.030 |
Why?
| | Trachoma | 1 | 1996 | 2 | 0.030 |
Why?
| | Corneal Diseases | 1 | 1997 | 45 | 0.030 |
Why?
| | Photic Stimulation | 1 | 1997 | 257 | 0.030 |
Why?
| | Viral Load | 1 | 1998 | 507 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2018 | 223 | 0.030 |
Why?
| | Neutropenia | 1 | 1997 | 151 | 0.030 |
Why?
| | Cerebral Infarction | 1 | 1996 | 49 | 0.030 |
Why?
| | Electroencephalography | 1 | 1999 | 522 | 0.030 |
Why?
| | Inpatients | 1 | 2020 | 513 | 0.030 |
Why?
| | Brain Edema | 1 | 1996 | 63 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1671 | 0.030 |
Why?
| | Health Status | 1 | 2021 | 822 | 0.030 |
Why?
| | Carotid Artery, Internal | 1 | 1995 | 44 | 0.030 |
Why?
| | Carotid Artery Diseases | 1 | 1995 | 62 | 0.030 |
Why?
| | Fractures, Bone | 1 | 2000 | 407 | 0.030 |
Why?
| | Multiple Sclerosis | 1 | 2000 | 468 | 0.030 |
Why?
| | Brain Injuries | 1 | 2000 | 503 | 0.030 |
Why?
| | Equipment Contamination | 1 | 1995 | 71 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 1312 | 0.030 |
Why?
| | Fundus Oculi | 1 | 1994 | 86 | 0.030 |
Why?
| | Child Abuse | 1 | 2020 | 548 | 0.030 |
Why?
| | Ceftazidime | 1 | 1994 | 6 | 0.030 |
Why?
| | Lacrimal Duct Obstruction | 1 | 2014 | 8 | 0.030 |
Why?
| | Anesthesia, Local | 1 | 2014 | 25 | 0.030 |
Why?
| | Aminoglycosides | 1 | 1994 | 26 | 0.030 |
Why?
| | Corneal Injuries | 1 | 1994 | 49 | 0.030 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2014 | 76 | 0.020 |
Why?
| | Karyotyping | 1 | 1993 | 104 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 5948 | 0.020 |
Why?
| | Emulsions | 1 | 1992 | 56 | 0.020 |
Why?
| | Foreign-Body Reaction | 1 | 1992 | 33 | 0.020 |
Why?
| | Prednisone | 1 | 1993 | 228 | 0.020 |
Why?
| | Eye Enucleation | 1 | 2011 | 15 | 0.020 |
Why?
| | Mutation | 1 | 2023 | 4006 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 1993 | 502 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3577 | 0.020 |
Why?
| | Primary Health Care | 1 | 2022 | 1757 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2001 | 1747 | 0.020 |
Why?
| | Muscle Denervation | 1 | 1991 | 8 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3172 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1994 | 1362 | 0.020 |
Why?
| | RNA Splice Sites | 1 | 2010 | 50 | 0.020 |
Why?
| | Injections, Intraocular | 1 | 2010 | 13 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2011 | 367 | 0.020 |
Why?
| | Tubocurarine | 1 | 1989 | 6 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 396 | 0.020 |
Why?
| | Exons | 1 | 2010 | 352 | 0.020 |
Why?
| | Fixatives | 1 | 1988 | 13 | 0.020 |
Why?
| | RNA Splicing | 1 | 2010 | 271 | 0.020 |
Why?
| | Molecular Weight | 1 | 1988 | 326 | 0.020 |
Why?
| | Neurofilament Proteins | 1 | 1988 | 62 | 0.020 |
Why?
| | Ganglia, Spinal | 1 | 1988 | 88 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 4180 | 0.020 |
Why?
| | Selection Bias | 1 | 2007 | 38 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 1988 | 381 | 0.020 |
Why?
| | Reflex | 1 | 1987 | 71 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1724 | 0.020 |
Why?
| | Obesity | 1 | 2000 | 3007 | 0.020 |
Why?
| | Hindlimb | 1 | 1987 | 133 | 0.020 |
Why?
| | Lung | 1 | 2020 | 4051 | 0.020 |
Why?
| | Axons | 1 | 1988 | 198 | 0.020 |
Why?
| | Attitude to Health | 1 | 2010 | 451 | 0.020 |
Why?
| | Lung Diseases | 1 | 1993 | 779 | 0.020 |
Why?
| | Body Weight | 1 | 1991 | 992 | 0.020 |
Why?
| | Phosphoproteins | 1 | 1988 | 332 | 0.020 |
Why?
| | Motor Neurons | 1 | 1988 | 234 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 2911 | 0.020 |
Why?
| | Spinal Cord | 1 | 1988 | 374 | 0.010 |
Why?
| | Action Potentials | 1 | 1989 | 505 | 0.010 |
Why?
| | Internet | 1 | 2010 | 683 | 0.010 |
Why?
| | Korea | 1 | 2005 | 17 | 0.010 |
Why?
| | Electromyography | 1 | 1987 | 411 | 0.010 |
Why?
| | Odds Ratio | 1 | 2007 | 1057 | 0.010 |
Why?
| | Video Games | 1 | 2005 | 30 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 771 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2006 | 269 | 0.010 |
Why?
| | Sympathectomy, Chemical | 1 | 2004 | 5 | 0.010 |
Why?
| | Reading | 1 | 2005 | 136 | 0.010 |
Why?
| | Patient Selection | 1 | 2007 | 685 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 2006 | 612 | 0.010 |
Why?
| | Risk Assessment | 1 | 2011 | 3522 | 0.010 |
Why?
| | Neurologic Examination | 1 | 2000 | 127 | 0.010 |
Why?
| | Cerebrospinal Fluid Pressure | 1 | 1999 | 3 | 0.010 |
Why?
| | Spinal Puncture | 1 | 1999 | 18 | 0.010 |
Why?
| | Acetazolamide | 1 | 1999 | 26 | 0.010 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 1999 | 40 | 0.010 |
Why?
| | Intracranial Pressure | 1 | 1999 | 61 | 0.010 |
Why?
| | Reaction Time | 1 | 1999 | 433 | 0.010 |
Why?
| | Cohort Studies | 1 | 2007 | 5809 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 1999 | 1043 | 0.010 |
Why?
| | Facial Pain | 1 | 1995 | 13 | 0.010 |
Why?
| | Isotonic Solutions | 1 | 1995 | 39 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1995 | 172 | 0.010 |
Why?
| | Survival Rate | 1 | 1999 | 1979 | 0.010 |
Why?
| | Magnetic Resonance Angiography | 1 | 1995 | 248 | 0.010 |
Why?
| | Radiography | 1 | 1995 | 845 | 0.010 |
Why?
|
|
Donahue's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|